CLAIMS

1. Association of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2*H*-3-benzazepin-2-one, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, with perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms, for the manufacture of a medicament ~~use in~~for the treatment of heart failure with preserved systolic function.

2. Association according to claim 1, characterised in that ivabradine is in the form of a hydrochloride, or one of its hydrates or crystalline forms.

3. Association according to one of claims 1 to 2, characterised in that the perindopril is in the form of a *tert*-butylami ne of their hydrates or crystalline forms.

4. Association according to claim 1, characterised in that ivabradine is in the form of a hydrochloride or one of its hydrates or crystalline forms, and perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

5. Pharmaceutical compositions comprising as active ingredients:

- ivabradine, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, and
- perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms,

on their own or in combination with one or more pharmaceutically acceptable excipients,

for the manufacture of a medicament ~~use in~~ for the treatment of heart failure with preserved systolic function.

6. Pharmaceutical composition according to claim 5, characterised in that ivabradine is in the form of a hydrochloride, or one of its hydrates or crystalline forms.

7. Pharmaceutical composition according to claim 5, characterised in that perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

8. Pharmaceutical composition according to claim 5, characterised in that ivabradine is in the form of a hydrochloride or one of its hydrates or crystalline forms, and perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.